Last reviewed · How we verify

NCT03325647: TESTO

TESTO: Testosterone Effects on Short-Term Outcomes in Infants With XXY

Completed Phase 4 Last updated 6 May 2022
What this trial tests

Phase 4 trial testing Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution in Klinefelter Syndrome in 72 participants. Completed in 5 May 2021.

Timeline
6 November 2017
Primary endpoint
5 May 2021
5 May 2021

Quick facts

Lead sponsorUniversity of Colorado, Denver
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingdouble
Primary purposetreatment
Enrollment72
Start date6 November 2017
Primary completion5 May 2021
Estimated completion5 May 2021
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Colorado, Denver

Who can join

Adults 31 Days to 90 Days, male only, with Klinefelter Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research study in infant males with Klinefelter syndrome (47,XXY) will learn more about the effect of testosterone on early health and development. The study is a total of three visits over 6 months with assessments of motor skills, body composition (muscle and fat), and hormone levels. This is a randomized, placebo-controlled study but all infants will receive testosterone treatment during the study period. The investigators will learn how testosterone treatment in infancy effects short term outcome measures on health and development.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Testosterone Treatment in Infants With 47,XXY: Effects on Body Composition.
    Davis SM, Reynolds RM, Dabelea DM, Zeitler PS, et al · · 2019 · cited 28× · PMID 31737857 · DOI 10.1210/js.2019-00274
  2. Morbidity in Klinefelter syndrome and the effect of testosterone treatment.
    Chang S, Skakkebaek A, Davis SM, Gravholt CH. · · 2020 · cited 27× · PMID 32496001 · DOI 10.1002/ajmg.c.31798
  3. Minipuberty in Klinefelter syndrome: Current status and future directions.
    Aksglaede L, Davis SM, Ross JL, Juul A. · · 2020 · cited 27× · PMID 32476267 · DOI 10.1002/ajmg.c.31794
  4. Early developmental impact of sex chromosome trisomies on attention deficit-hyperactivity disorder symptomology in young children.
    Kuiper K, Swaab H, Tartaglia N, van Rijn S. · · 2021 · cited 19× · PMID 34240550 · DOI 10.1002/ajmg.a.62418
  5. The developmental impact of sex chromosome trisomies on emerging executive functions in young children: Evidence from neurocognitive tests and daily life skills.
    Kuiper KC, Swaab H, Tartaglia N, van Buggenhout G, et al · · 2022 · cited 8× · PMID 35584398 · DOI 10.1111/gbb.12811
  6. Early symptoms of autism spectrum disorder (ASD) in 1-8 year old children with sex chromosome trisomies (XXX, XXY, XYY), and the predictive value of joint attention.
    Bouw N, Swaab H, Tartaglia N, Wilson RL, et al · · 2023 · cited 7× · PMID 36107256 · DOI 10.1007/s00787-022-02070-y
  7. (Not) getting what you want: frustration and emotion regulation in children with sex chromosome trisomies.
    Kuiper K, Swaab H, Tartaglia N, van Rijn S. · · 2023 · cited 1× · PMID 37183811 · DOI 10.1530/ec-22-0442

Verify or expand the search:

Other recruiting trials for Klinefelter Syndrome

Currently open trials in the same condition.

Other University of Colorado, Denver trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03325647.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing